NOV 28, 2015 6:44 AM PST

Rare Tropical Disease Puts Transplant Patients At Risk

WRITTEN BY: Kara Marker
Leishmaniasis is an infectious disease caused by the bite of parasite-infected sand flies, and it's usually found in tropical regions and southern Europe. The infection can be either cutaneous, causing skin sores, or visceral, affecting internal organs (CDC). The number of leishmaniasis infections has quadrupled since the 1990s, and researchers from Spain looked to calculate the risk and determine how to prevent infections in vulnerable transplant patients. 
 Geographical distribution of visceral leishmaniasis

In a recent study published in PLoS Neglected Tropical Diseases, scientists looked at 63 individuals who had received solid organ transplants and worked to determine the number of patients who had come into contact with the parasite and what their risk was of developing leishmaniasis at any point for the rest of their lives. Because of the immunosuppressive therapy transplant patients receive to prevent organ rejection, these patients have a 100 times greater risk of developing severe visceral leishmaniasis compared to immunocompetent people.

The team conducted two tests scanning for any form of leishmaniasis infection. One test involved experimental lymphocyte proliferation assays and cytokine production analysis, to examine how the immune system was working, potentially hinting at a leishmaniasis invasion. The second test was more routine - "serologic and parasitology tests" that are normally used to diagnose cases of leishmaniasis. 

The scientists saw a correlation between the two tests, and this initial success points to the experimental assays as new indicators of leishmaniasis progression at various stages of infection. Continuing studies with these analytic tests could help scientists understand the relationship between transplant patients and their lifetime risk of developing leishmaniasis. 

Ultimately, the team is interested in preventing the initial transmission of leishmaniasis as well as relapse recovery. Identifying which immunocompromised patients are at high risk of relapsing with infection could help doctors know when to administer additional chemotherapeutics to prevent additional infections in individuals not completely recovered. 

"Being the recipient of an organ tranplant is increasingly common amoung the Spanish population," said Dr. Javier Moreno, team researcher. "As a consequence, it is necessary to both prevent the risk of infection in transplant patients and to adopt appropriate measures for disease management and prevention in clinical cases in order to prevent relapses."

Watch the following video to learn more about leishmaniasis. 

Source: Plataforma SINC
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 02, 2020
Immunology
Stop the Clot: A New Antibody Treatment for Thrombosis
OCT 02, 2020
Stop the Clot: A New Antibody Treatment for Thrombosis
Blood clotting helps stem the bleeding from a wound, suppressing blood loss and stopping pathogenic microorganisms from ...
OCT 22, 2020
Immunology
Migraines: Dark Times and (Pharmaceutical) Rays of Hope
OCT 22, 2020
Migraines: Dark Times and (Pharmaceutical) Rays of Hope
Despite being commonly used interchangeably, headaches and migraines are worlds apart. Migraines are by far much more pr ...
OCT 22, 2020
Cell & Molecular Biology
How a Gene Variant Raises the Risk of Multiple Sclerosis
OCT 22, 2020
How a Gene Variant Raises the Risk of Multiple Sclerosis
Now that sequencing the whole human genome is easier, faster, and cheaper than it used to be, scientists have been able ...
DEC 20, 2020
Microbiology
How Do mRNA Vaccines Work?
DEC 20, 2020
How Do mRNA Vaccines Work?
Scientist Katalin Karikó studied mRNA vaccines for years. She spent years getting grant rejections, but has now helped c ...
DEC 28, 2020
Genetics & Genomics
Mapping Networks of Gene Expression in Cells
DEC 28, 2020
Mapping Networks of Gene Expression in Cells
Every cell contains our whole genome, but not all genes are turned on all the time; gene expression has to be very caref ...
JAN 12, 2021
Immunology
Killer Control: Engineered Stem Cells Dodge Transplant Rejection
JAN 12, 2021
Killer Control: Engineered Stem Cells Dodge Transplant Rejection
The first organ transplant—performed over 60 years ago—was a success because the donor and recipient were id ...
Loading Comments...